IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production

Journal of Immunology

Volumn 178, Issue 5, 2007, Pages 2827-2834

  Coquet, Jonathan M ^a   Kyparissoudis, Konstantinos ^a   Pellicci, Daniel G ^a   Besra, Gurdyal ^b   Berzins, Stuart P ^a   Smyth, Mark J ^c   Godfrey, Dale I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD94 ANTIGEN; CYTOKINE; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; LY49 RECEPTOR; NATURAL KILLER CELL RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOCRINE EFFECT; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR REJECTION;

EID: 33847367120     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.5.2827     Document Type: Article

References (61)

1. Godfrey, D. I., and M. Kronenberg. 2004. Going both ways; immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114: 1379-1388.
2. Godfrey, D. I., H. R. MacDonald, M. Kronenberg, M. J. Srayth, and L. Van Kaer. 2004. NKT cells: what's in a name? Nat. Rev. Immunol. 4: 231-237.
3. Brigl, M., and M. B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22: 817-890.
4. Kawano, T., J. Q. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. Cd1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278: 1626-1629.
5. Nishimura, T., H. Kitamura, K. Iwakabe, T. Yahata, A. Ohta, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, T. Kawano, et al. 2000. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol. 12: 987-994.
6. + T cells for the antitumor immunity induced in the liver of mice by α-galactosylceramide. J. Immunol. 172: 6550-6557.
7. Eberl, G., and H. R. MacDonald. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30: 985-992.
8. Carnaud, C., D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650.
9. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189: 1121-1127.
10. Fujii, S., K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198: 267-279.
11. Kitamura, H., A. Ohta, M. Sekimoto, M. Sato, K. Iwakabe, M. Nakui, T. Yahata, H. X. Meng, T. Koda, S. Nishimura, et al. 2000. α- Galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell. Immunol. 199: 37-42.
12. Crowe, N. Y., M. J. Smyth, and D. I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196: 119-127.
13. Smyth, M. J., N. Y. Crowe, and D. I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13: 459-463.
14. van Dommelen, S. L., H. A. Tabarias, M. J. Smyth, and M. A. Degli-Esposti. 2003. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J. Virol. 77: 1877-1884.
15. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389.
16. Giaccone, G., C. J. A. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. E. von Blomberg, R. J. Scheper, H. J. J. van der Vliet, A. J. M. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8: 3702-3709.
17. Ishikawa, A., S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa. 2005. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11: 1910-1917.
18. Chang, D. H., K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201: 1503-1517.
19. Smyth, M. J., M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201: 1973-1985.
20. Asao, H., C. Okuyama, S. Kumaki, N. Ishii, S. Tsuchiya, D. Foster, and K. Sugamura. 2001. Cutting edge: the common γ-chain is an indispensable sub-unit of the IL-21 receptor complex. J. Immunol. 167: 1-5.
21. c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41: 8725-8731.
22. Jin, H., R. Carrio, A. Yu, and T. R. Malek. 2004. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173: 657-665.
23. Mehta, D. S., A. L. Wurster, M. J. Whitters, D. A. Young, M. Collins, and M. J. Grusby. 2003. IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 170: 4111-4118.
24. Parrish-Novak, J., S. R. Dillon, A. Nelson, A. Hammond, C. Sprecher, J. A. Gross, J. Johnston, K. Madden, W. Xu, J. West, et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63.
25. Ozaki, K., R. Spolski, C. G. Feng, C. F. Qi, J. Cheng, A. Sher, H. C. Morse, III, C. Liu, P. L. Schwartzberg, and W. J. Leonard. 2002. A critical role for IL-21 in regulating immunoglobulin production. Science 298: 1630-1634.
26. Brandt, K., S. Bulfone-Paus, D. C. Foster, and R. Ruckert. 2003. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102: 4090-4098.
27. Brandt, K., S. Bulfone-Paus, A. Jenckel, D. C. Foster, R. Paus, arid R. Ruckert. 2003. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J. Invest. Dermatol. 121: 1379-1382.
28. Eberl, M., R. Engel, E. Beck, and H. Jomaa. 2002. Differentiation of human γ-δ T cells towards distinct memory phenotypes. Cell Immunol. 218: 1-6.
29. + T cell expansion and function. J. Exp. Med. 201: 139-148.
30. Ma, H. L., M. J. Whitters, R. F. Konz, M. Senices, D. A. Young, M. J. Grusby, M. Collins, and K. Dunussi-Joannopoulos. 2003. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perform but are independent of IFN-γ. J. Immunol. 171: 608-615.
31. Kishida, T., H. Asada, Y. Itokawa, F. D. Cui, M. Shin-Ya, S. Gojo, K. Yasutomi, Y. Ueda, H. Yamagishi, J. Imanishi, and O. Mazda. 2003. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 8: 552-558.
32. Wang, G., M. Tschoi, R. Spolski, Y. Lou, K. Ozaki, C. Feng, O. Kim, W. J. Leonard, and P. Hwu. 2003. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63: 9016-9022.
33. Leonard, W. J., and R. Spolski. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5: 688-698.
34. Curti, B. D. 2006. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev. Anticancer Ther. 6: 905-909.
35. King, C., A. Ilic, K. Koelsch, and N. Sarvetnick. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117: 265-277.
36. + T cells. J. Immunol. 162: 7067-7074.
37. Kadowaki, N., S. Antonenko, S. Ho, M. C. Rissoan, V. Soumelis, S. A. Porcelli, L. L. Lanier, and Y. J. Liu. 2001. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J. Exp. Med. 193: 1221-1226.
38. Lin, H., M. Nieda, and A. J. Nicol. 2004. Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur. J. Immunol. 34: 2664-2671.
39. + cell development. J. Immunol. 159: 5931-5935.
40. Matsuda, J. L., L. Gapin, S. Sidobre, W. C. Kieper, J. Y. T. Tan, R. Ceredig, C. D. Surh, and M. Kronenberg. 2002. Homeostasis of Vα14i NKT cells. Nat. Immunol. 3: 966-974.
41. Baxevanis, C. N., A. D. Gritzapis, and M. Papamichail. 2003. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J. Immunol. 171: 2953-2959.
42. Smyth, M. J., M. Taniguchi, and S. E. A. Street. 2000. The anti-tumor activity of IL-12: mechanisms of innate immunity,that are model and dose dependent. J. Immunol. 165: 2665-2670.
43. Cui, J. Q., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626.
44. Leite-De-Moraes, M. C., A. Hameg, A. Amould, F. Machavoine, Y. Koezuka, E. Schneider, A. Herbelin, and M. Dy. 1999. A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement. J. Immunol. 163: 5871-5876.
45. Leite-De-Moraes, M. C., A. Hameg, M. Pacilio, Y. Koezuka, M. Taniguchi, L. Van Kaer, E. Schneider, M. Dy, and A. Herbelin. 2001. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J. Immunol. 166: 945-951.
46. Smyth, M. J., K. Y. T. Thia, S. E. A. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:661-668.
47. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C. R. Wang, Y. Koezuka, and M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192: 741-753.
48. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99: 1259-1266.
49. Kasaian, M. T., M. J. Whitters, L. L. Carter, L. D. Lowe, J. M. Jussif, B. Deng, K. A. Johnson, J. S. Witek, M. Senices, R. F. Konz, et al. 2002. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16: 559-569.
50. Brady, J., Y. Hayakawa, M. J. Smyth, and S. L. Nutt. 2004. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172: 2048-2058.
51. Uldrich, A. P., N. Y. Crowe, K. Kyparissoudis, D. O. Pellicci, Y. Zhan, A. M. Lew, P. Bouillet, A. Strasser, M. J. Smyth, and D. I. Godfrey. 2005. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175: 3092-3101.
52. Monteleone, G., I. Monteleone, D. Fina, P. Vavassori, G. Del Vecchio Blanco, R. Caruso, R. Tersigni, L. Alessandroni, L. Biancone, G. C. Naccari, et al. 2005. Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn's disease. Gastroenterology 128: 687-694.
53. Matsuda, J. L., Q. Zhang, R. Ndonye, S. K. Richardson, A. R. Howell, and L. Gapin. 2006. T-bet concomitantly controls migration, survival and effector functions during the development of Vα14i NKT cells. Blood 107: 2797-2805.
54. Dou, J., G. Chen, J. Wang, F. Zhao, J. Chen, X. Fang, Q. Tang, and L. Chu. 2004. Preliminary study on mouse interleukin-21 application in tumor gene therapy. Cell. Mol. Immunol. 1: 461-466.
55. Di Carlo, E., A. Comes, A. M. Orengo, O. Rosso, R. Meazza, P. Musiani, M. P. Colombo, and S. Ferrini. 2004. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. 172: 1540-1547.
56. Mallevaey, T., J. P. Zanetta, C. Faveeuw, J. Fontaine, E. Maes, F. Platt, M. Capron, M. L. de-Moraes, and F. Trottein. 2006. Activation of invariant NKT cells by the helminth parasite Schistosoma mansoni. J. Immunol. 176: 2476-2485.
57. Pesce, J., M. Kaviratne, T. R. Ramalingam, R. W. Thompson, J. F. Urban, A. W. Cheever, D. A. Young, M. Collins, M. J. Grusby, and T. A. Wynn. 2006. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116: 2044-2055.
58. Vollmer, T. L., R. Liu, M. Price, S. Rhodes, A. La Cava, and F. D. Shi. 2005. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174: 2696-2701.
59. Nakano, H., T. Kishida, H. Asada, M. Shin-Ya, T. Shinomiya, J. Imanishi, T. Shimada, S. Nakai, M. Takeuchi, Y. Hisa, and O. Mazda. 2006. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J. Gene Med. 8: 90-99.
60. Li, Y., M. Bleakley, and C. Yee. 2005. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175: 2261-2269.
61. Hansen, D. S., and L. Schofield. 2004. Regulation of immunity and pathogenesis in infectious diseases by CD1d-restricted NKT cells. Int. J. Parasitol. 34: 15-25.